Bayer’s Xarelto Wins EU Drug Panel Backing for Added Uses
This article is for subscribers only.
Bayer AG’s Xarelto won the backing of a European drug advisory panel for use in irregular-heartbeat patients, putting the blood thinner in line for approval in a market that may reach $9 billion in annual sales worldwide.
The Committee for Medicinal Products for Human Use also recommended Xarelto to treat deep vein thrombosis, or clots in the legs or lungs, the European Medicines Agency said in a statement on its website today.